obesity-treatment
16 stories related to this topic, newest first.
finance.yahoo.comEli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
benzinga.comEli Lilly Reports Retatrutide Weight Loss Results in Phase 3 Trial
Eli Lilly reported results from a late-stage trial of its obesity drug retatrutide. Patients who stayed on the highest dose lost an average of 28.3 percent of their body weight after 80 weeks.
Studies Find Modest Reductions in Migraine Drug Use and Asthma Exacerbations Among People Taking GLP-1RA Medications
Research presented at the European Congress on Obesity in Turkey found that Wegovy was associated with a 7 per cent reduction in triptan use among women with migraines and that GLP-1RA drugs correlated with a 26 per cent drop in asthma exacerbations. The studies drew on Danish he…
rediff.comExperimental Quintuple Agonist Outperforms Semaglutide in Mouse Obesity Models
A quintuple agonist developed by researchers at Helmholtz Munich combines GLP-1, GIP and PPAR activity to target five receptor systems. The compound reduced body weight, fat mass and blood sugar more effectively than existing therapies in several mouse models. Scientists caution…
nbcnews.comDaily Pill Maintains 70% of Weight Loss vs 38-50% on Placebo One Year After Stopping GLP-1 Injections
A new study shows patients taking daily orforglipron kept more than 70 percent of prior weight loss after one year off jabs, compared with 38-50 percent for those on placebo. The Eli Lilly drug, already available in the US at around $149 per month for the lowest dose, offers a ch…
forbes.comOral Weight Loss Pill Orforglipron Helps Maintain Results After Injectable GLP-1 Drugs
Two randomized studies published in Nature Medicine show patients who switched from tirzepatide or semaglutide to daily oral orforglipron maintained 75 to 79 percent of their weight loss after one year, compared with 38 to 49 percent for those on placebo. The trial involved 376 p…
nypost.comOral Orforglipron Maintains Modest Weight Loss After Stopping Injectables, Trial Finds
A Nature Medicine study found that daily oral orforglipron allowed patients to retain most of their weight reduction after stopping tirzepatide or semaglutide injections. The trial of 376 U.S. participants showed significantly better maintenance than placebo. The drug, approved l…
The Boston GlobeReader Responses to GLP-1 Weight Loss Drugs and Insurance Coverage Changes
Readers of The Boston Globe have shared varied opinions on GLP-1 medications for obesity treatment following a February 22 article. Some highlight the drugs' benefits for health conditions beyond weight loss, while others question obesity as a disease and oppose insurance subsidi…
Substrate placeholder — needs reviewStudy Identifies Genetic Variations Influencing Response to Weight-Loss Drugs Wegovy and Mounjaro
Researchers analyzed genetic data from 15,000 individuals to identify variations linked to weight-loss outcomes and side effects from medications like Wegovy and Mounjaro. The study, published in Nature, found that certain variants affect weight reduction and nausea or vomiting s…
Substrate placeholder — needs reviewEli Lilly Launches Oral GLP-1 Medication Orforglipron for Weight Loss in the United States
Eli Lilly and Company has introduced Foundayo, the brand name for orforglipron, an oral GLP-1 receptor agonist approved for weight management. The pill offers a non-injectable alternative to existing treatments in the growing obesity drug market. Availability begins in the US, ta…
sciencenews.orgGenomic and Demographic Data Enable Prediction of GLP-1 Drug Weight Loss Response
Researchers have identified that genomic and demographic data can predict the magnitude of weight loss from GLP-1 drugs. This approach involves analysis by 23andMe. The findings focus on drug response and side effects in obesity treatment.
Substrate placeholder — needs reviewResearchers Identify Genetic Variants Linked to Variable Responses to Obesity Drugs
Scientists have identified genetic variants that may explain differences in individual responses to obesity medications. The findings, published in Nature, analyzed data from clinical trials involving drugs like semaglutide. This research highlights the role of genetics in person…
sciencenews.orgGenetic Variants Linked to Weight Loss Outcomes and Side Effects from GLP-1 Drugs
A study published in Nature identifies variations in two genes associated with greater weight loss and increased side effects from GLP-1 receptor agonist drugs like Wegovy and Mounjaro. The research, based on data from 15,000 to nearly 28,000 23andMe users, shows modest genetic i…
neurosciencenews.comGenetic Variants Linked to Weight Loss Outcomes on GLP-1 Drugs in New Study
A study published in Nature identifies variations in two genes associated with greater weight loss and side effects from GLP-1 receptor agonist drugs like Wegovy and Mounjaro. The research, based on data from 15,000 to 28,000 users, shows these genetic factors contribute modestly…
sciencenews.orgGenetic Variations in Two Genes Linked to Weight Loss and Side Effects from GLP-1 Drugs
Research indicates that variations in two genes associated with appetite and digestion can predict greater weight loss in patients using GLP-1 drugs for obesity treatment. These genetic changes also correlate with increased risk of nausea and vomiting as side effects. The finding…
Hunted230 / Wikimedia (CC BY-SA 3.0)First-Time Users of Weight-Loss Medicines Seek Lower Costs and Greater Convenience from Novo Nordisk and Eli Lilly Pills
Seven doctors specializing in obesity report that Americans beginning weight-loss treatments prioritize reduced costs and improved convenience. These patients are evaluating oral medications from Novo Nordisk and Eli Lilly. The preferences reflect ongoing discussions in the obesi…